Effect of mannitol on the pharmacokinetics of amikacin in wistar rats

Olguı́n, Hugo Juárez; Portugal, Miriam Carrasco; Flores‐Pérez, Janett; Vieyra, Angélica Camacho; Pérez, Carmen Flores; Rodríguez, Alfonso Alfaro

doi:10.1590/s1516-89132009000400006

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After this, a dose of 10 mg kg -1 of amikacin (Amikin®, Bristol-Myers Pharmaceuticals, Middlesex, England) was administered intraperitoneally to the rats every 24 h for 3 consecutive days. Of note, similar amikacin dosing in rats has been reported elsewhere [8].…”

Section: Drug Administrationsupporting

confidence: 65%

Animal model investigation suggests betamethasone alters the pharmacokinetics of amikacin

Amponsah¹,

Opuni

Donkor³

2018

ADMET DMPK

View full text Add to dashboard Cite

Corticosteroids, such as betamethasone, are sometimes administered to women who are at risk of pre-term delivery. These corticosteroids cross the placenta to the fetus and decrease respiratory distress syndrome in preterm newborns. Preterm newborns are often susceptible to infections partly due to their immature immune system. Amikacin is one of the aminoglycosides used in the treatment of newborn infections. There is, however, a dearth of information on the effect of prenatal corticosteroids on the disposition of aminoglycosides administered to newborns days later. We evaluated the effect of pre-administration of betamethasone on the disposition of amikacin, 72 h after last dose of betamethasone, using an animal model. The pharmacokinetic parameters of rats administered betamethasone followed by amikacin vis-a-vis rats administered saline followed by amikacin were as follows: Cmax; 16.6 μmol L-1 vs. 31.4 μmol L-1, AUC0→8; 26.8 μmol h L-1 vs. 153.5 μmol h L-1, Ke; 0.26 h-1 vs. 0.18 h-1, and t1/2; 2.6 h vs. 3.9 h, respectively. About a 1.5-fold increase in the elimination of amikacin was observed in the Sprague-Dawley rats pre-treated with betamethasone compared with those pre-treated with saline. This ultimately led to differences in the other pharmacokinetic parameters amongst the two groups of rats. Although an animal model investigation showed some level of interaction, a follow-up study in preterm newborns where possible interaction of the two drugs is studied later than Day 1, is recommended.

show abstract

Section: Drug Administrationsupporting

confidence: 65%

Animal model investigation suggests betamethasone alters the pharmacokinetics of amikacin

Amponsah¹,

Opuni

Donkor³

2018

ADMET DMPK

View full text Add to dashboard Cite

show abstract

“…According to Edward et al (1993), Amikacin administration resulted in peak values of 27.3 ± 6.9 μg/ml in study of the pharmacokinetic properties of Gentamicin and Amikacin in the Cockatiel. In case of Wistar Rats, Hugo et al [9] analysed the effect of mannitol on the pharmacokinetics (PK) of amikacin and C max were evaluated as 62.26 ± 15.75 mg/ml, 72.63 ± 24.80 mg/ml and 68.61 ± 27.40 mg/ml for three different groups.…”

Section: Discussionmentioning

confidence: 99%

Effect of Withania somnifera (Ashwagandha) on the Pharmacokinetics of Amikacin: A Future Antimicrobial Polypharmacy

Dahikar¹

2012

J Drug Metab Toxicol

View full text Add to dashboard Cite

Citation: Dahikar PR, Kumar N, Sahni YP (2013) Effect of Withania somnifera (Ashwagandha) on the Pharmacokinetics of Amikacin: A Future Antimicrobial Polypharmacy. AbstractThe pharmacokinetic study of Amikacin with interaction of W. somnifera was investigated after single administration of 10 mg/kg of Amikacin intravenously and 500 mg/kg of W. somnifera orally in six non-descript healthy buffalo calves. Estimation of concentration of Amikacin in plasma was carried out by microbiological assay technique (Agar gel diffusion technique) by using Escherichia coli (ATCC 25922) as test organism. Following a single administration of 10 mg/kg of Amikacin intravenously and 500 mg/kg of W. somnifera orally in six non-descript healthy buffalo calves, plasma concentration of Amikacin, at 1 min of combined administration of these drugs were 17.05 ± 0.28 µg/ml. The effective therapeutic concentration of Amikacin (≥ 1.0 µg/ml) was maintained up to 24 h with mean value of 1.86 ± 0.038 µg/ml. The mean distribution half-life of phase 1 (t 1/2 α 1 ), phase 2 (t 1/2 α 2 ) and elimination half-life (t 1/2 β) were calculated to be 0.060 ± 0.004, 3.99 ± 0.27 and 6.15 ± 0.21 h, respectively whereas the total body clearance (Cl B ) was ranged from 0.064 to 0.075 L/kg/h with a mean of 0.068 0.002 L/kg/h. A satisfactory intravenous dosage regimen of Amikacin in buffalo calves after combined administration would be 2.36 ± 0.095 mg/kg followed by 1.75 ± 0.10 mg/kg at 12 h interval supports the excellent clinical efficacy of Amikacin in buffalo calves.

show abstract

Effect of mannitol on the pharmacokinetics of amikacin in wistar rats

Abstract: The study analyzed the effect of mannitol on the pharmacokinetics (PK)

Cited by 2 publications

References 7 publications

Animal model investigation suggests betamethasone alters the pharmacokinetics of amikacin

Animal model investigation suggests betamethasone alters the pharmacokinetics of amikacin

Effect of Withania somnifera (Ashwagandha) on the Pharmacokinetics of Amikacin: A Future Antimicrobial Polypharmacy

Contact Info

Product

Resources

About